Zolpimist® (zolpidem tartrate) is a patented, FDA approved bioequivalent version of the market leading sleep aid, Ambien® in an oral spray formulation.
Zolpidem is the most commonly prescribed agent for the treatment of insomnia with a market share of approximately 70%, with over 1.2 billion zolpidem tablets prescribed in 2010 in the US.
Zolpimist® is engineered to outperform the oral tablets
Using a proprietary and patented technology we deliver the drug as a fine mist into the mucosal membranes lining the cheeks in the mouth (buccal delivery). This mode of delivery offers some very clear advantages as compared to other delivery methods:
Fast onset of action; Zolpimist® induces sleep three times faster than oral tablets – 10 minutes as compared to 30 – 40 minutes for oral tablets.
No food effect that mitigates the efficacy of other zolpidem products
Zolpimist® (zolpidem oral spray)
Approved by FDA December 2008; currently being sold by Hi-Tech Pharmacal ("HITK" Nasdaq), licensed from NovaDel Pharma.
Zolpidem, the active ingredient in both Ambien® (Sanofi-Aventis) and Zolpimist®, is the leading sleep aid on the market with an approximate market share of 70%.
Zolpimist® is a patented product developed and designed to provide patients with faster onset of sleep as demonstrated in various clinical studies.
Two dosages have been approved
5mg – one spray
- 10mg – two sprays